Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Krackhardt F. | - |
dc.contributor.author | Waliszewski M. | - |
dc.contributor.author | Wan Ahmad W.A. | - |
dc.contributor.author | Kočka V. | - |
dc.contributor.author | Toušek P. | - |
dc.contributor.author | Janek B. | - |
dc.contributor.author | Trenčan M. | - |
dc.contributor.author | Krajči P. | - |
dc.contributor.author | Lozano F. | - |
dc.contributor.author | Roman K.G.-S. | - |
dc.contributor.author | Irurueta I.O. | - |
dc.contributor.author | del Blanco B.G. | - |
dc.contributor.author | Wachowiak L. | - |
dc.contributor.author | del Olmo V.V. | - |
dc.contributor.author | Nofrerías E.F. | - |
dc.contributor.author | Jeong M.H. | - |
dc.contributor.author | Jung B.-C. | - |
dc.contributor.author | Han K.-R. | - |
dc.contributor.author | Piot C. | - |
dc.contributor.author | Sebagh L. | - |
dc.contributor.author | Rischner J. | - |
dc.contributor.author | Pansieri M. | - |
dc.contributor.author | Leschke M. | - |
dc.contributor.author | Ahn T.H. | - |
dc.date.available | 2020-03-03T06:44:35Z | - |
dc.date.created | 2020-02-24 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17707 | - |
dc.description.abstract | Background The objective of this study was to assess regional and ethnic differences in an unselected patient population treated with polymer-free sirolimus-eluting stents (PF-SES) in Asia and Europe. Methods Two all-comers observational studies based on the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were combined for data analysis to assure sufficient statistical power. The primary endpoint was the accumulated target lesion revascularization (TLR) rate at 9–12 months. Results Of the total population of 7243 patients, 44.0% (3186) were recruited in the Mediterranean region and 32.0% (2317) in central Europe. The most prominent Asian region was South Korea (17.6%, 1274) followed by Malaysia (5.7%, 413). Major cardiovascular risk factors varied significantly across regions. The overall rates for accumulated TLR and MACE were low with 2.2% (140/6374) and 4.4% (279/6374), respectively. In ACS patients, there were no differences in terms of MACE, TLR, MI and accumulated mortality between the investigated regions. Moreover, dual antiplatelet therapy (DAPT) regimens were substantially longer in Asian countries even in patients with stable coronary artery disease as compared to those in Europe. Conclusions PF-SES angioplasty is associated with low clinical event rates in all regions. Further reductions in clinical event rates seem to be associated with longer DAPT regimens. © 2020 Krackhardt et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Public Library of Science | - |
dc.relation.isPartOf | PLoS ONE | - |
dc.title | Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000534352500017 | - |
dc.identifier.doi | 10.1371/journal.pone.0226606 | - |
dc.identifier.bibliographicCitation | PLoS ONE, v.15, no.1 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85077765638 | - |
dc.citation.title | PLoS ONE | - |
dc.citation.volume | 15 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Ahn T.H. | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | acetylsalicylic acid | - |
dc.subject.keywordPlus | clopidogrel | - |
dc.subject.keywordPlus | heparin | - |
dc.subject.keywordPlus | polymer | - |
dc.subject.keywordPlus | prasugrel | - |
dc.subject.keywordPlus | rapamycin | - |
dc.subject.keywordPlus | thienopyridine derivative | - |
dc.subject.keywordPlus | ticagrelor | - |
dc.subject.keywordPlus | vitamin K group | - |
dc.subject.keywordPlus | acute coronary syndrome | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | Asia | - |
dc.subject.keywordPlus | cardiovascular mortality | - |
dc.subject.keywordPlus | cardiovascular risk | - |
dc.subject.keywordPlus | Central Europe | - |
dc.subject.keywordPlus | clinical outcome | - |
dc.subject.keywordPlus | cohort analysis | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | coronary artery disease | - |
dc.subject.keywordPlus | demography | - |
dc.subject.keywordPlus | drug choice | - |
dc.subject.keywordPlus | dual antiplatelet therapy | - |
dc.subject.keywordPlus | ethnic difference | - |
dc.subject.keywordPlus | Europe | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | heart infarction | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | major adverse cardiac event | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | Malaysia | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | observational study | - |
dc.subject.keywordPlus | South Korea | - |
dc.subject.keywordPlus | Southern Europe | - |
dc.subject.keywordPlus | target lesion revascularization | - |
dc.subject.keywordPlus | transluminal coronary angioplasty | - |
dc.subject.keywordPlus | treatment duration | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.